Evaluation and treatment of rhinosinusitis with primary antibody deficiency in children: Evidence-based review with recommendations.
antibody deficiency
chronic rhinosinusitis
evaluation
immunodeficiency disorders
recommendations
recurrent acute rhinosinusitis
treatment
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
revised:
29
08
2024
received:
30
07
2024
accepted:
24
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
15
10
2024
Statut:
aheadofprint
Résumé
There is clear evidence that prevalence of primary antibody deficiency (PAD) is higher in children with chronic rhinosinusitis (CRS) than in the general population. The purpose of this multi-institutional and multidisciplinary evidence-based review with recommendations (EBRR) is to thoroughly review the literature on rhinosinusitis with PAD, summarize the existing evidence, and provide recommendations on the evaluation and management of rhinosinusitis in children with PAD. The PubMed, Embase, and Cochrane databases were systematically reviewed from inception through December 2023. Studies on the evaluation and management of rhinosinusitis in PAD patients were included. An iterative review process was utilized in accordance with EBRR guidelines. Levels of evidence and recommendations on the evaluation and management principles for PAD were generated. A total of 50 studies were included in this evidence-based review. These studies were evaluated on the incidence of PAD in rhinosinusitis patients, the incidence of rhinosinusitis in PAD patients, and on the different treatment modalities used and their outcome. The aggregate quality of evidence varied across the reviewed domains. Based on the currently available evidence, the incidence of PAD in children with recalcitrant CRS can be significantly elevated. Despite the presence of multiple studies addressing rhinosinusitis and PAD, the level of evidence supporting different treatment options continues to be lacking. Optimal management requires a multidisciplinary approach through collaboration with clinical immunology. There is need for higher level studies that compare different treatments in children with PAD and rhinosinusitis.
Sections du résumé
BACKGROUND
BACKGROUND
There is clear evidence that prevalence of primary antibody deficiency (PAD) is higher in children with chronic rhinosinusitis (CRS) than in the general population. The purpose of this multi-institutional and multidisciplinary evidence-based review with recommendations (EBRR) is to thoroughly review the literature on rhinosinusitis with PAD, summarize the existing evidence, and provide recommendations on the evaluation and management of rhinosinusitis in children with PAD.
METHODS
METHODS
The PubMed, Embase, and Cochrane databases were systematically reviewed from inception through December 2023. Studies on the evaluation and management of rhinosinusitis in PAD patients were included. An iterative review process was utilized in accordance with EBRR guidelines. Levels of evidence and recommendations on the evaluation and management principles for PAD were generated.
RESULTS
RESULTS
A total of 50 studies were included in this evidence-based review. These studies were evaluated on the incidence of PAD in rhinosinusitis patients, the incidence of rhinosinusitis in PAD patients, and on the different treatment modalities used and their outcome. The aggregate quality of evidence varied across the reviewed domains.
CONCLUSION
CONCLUSIONS
Based on the currently available evidence, the incidence of PAD in children with recalcitrant CRS can be significantly elevated. Despite the presence of multiple studies addressing rhinosinusitis and PAD, the level of evidence supporting different treatment options continues to be lacking. Optimal management requires a multidisciplinary approach through collaboration with clinical immunology. There is need for higher level studies that compare different treatments in children with PAD and rhinosinusitis.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 ARS‐AAOA, LLC.
Références
Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213‐739. doi:10.1002/alr.22741
Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(S29):1‐464. doi:10.4193/Rhin20.600
Ramadan HH, Chaiban R, Makary C. Pediatric rhinosinusitis. Pediatr Clin North Am. 2022;69(2):275‐286. doi:10.1016/j.pcl.2022.01.002
Bhattacharyya N, Jones DT, Hill M, Shapiro NL. The diagnostic accuracy of computed tomography in pediatric chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg. 2004;130(9):1029‐1032. doi:10.1001/archotol.130.9.1029
Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186‐1205.e1‐78. doi:10.1016/j.jaci.2015.04.049
Mazza JM, Lin SY. Primary immunodeficiency and recalcitrant chronic sinusitis: a systematic review. Int Forum Allergy Rhinol. 2016;6(10):1029‐1033. doi:10.1002/alr.21789
Schwitzguébel AJ, Jandus P, Lacroix JS, Seebach JD, Harr T. Immunoglobulin deficiency in patients with chronic rhinosinusitis: systematic review of the literature and meta‐analysis. J Allergy Clin Immunol. 2015;136(6):1523‐1531. doi:10.1016/j.jaci.2015.07.016
Rudmik L, Smith TL. Development of an evidence‐based review with recommendations using an online iterative process. Int Forum Allergy Rhinol. 2011;1(6):431‐437. doi:10.1002/alr.20095
Levels of evidence. Oxford Centre for Evidence‐based Medicine (CEBM). Accessed October, 2022. http://www.cebm.net/index.aspx?o=1025
American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics. 2004;114(3):874‐877. doi:10.1542/peds.2004‐1260
Aghamohammadi A, Farhoudi A, Moin M, et al. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immunol. 2005;12(7):825‐832.
Aghamohammadi A, Moazzami K, Rezaei N, et al. ENT manifestations in Iranian patients with primary antibody deficiencies. J Laryngol Otol. 2008;122(4):409‐413.
Azizi G, Tavakol M, Yazdani R, et al. Autoimmune manifestations among 461 patients with monogenic inborn errors of immunity. Pediatr Allergy Immunol. 2021;32(6):1335‐1348. doi:10.1111/pai.13510
Behnke J, Jimenez‐Herrera P, Peppers B, Ramadan HH, Makary CA. Outcome of immunoglobulin replacement therapy in children with rhinosinusitis. Int Forum Allergy Rhinol. 2022;12(5):795‐797. doi:10.1002/alr.22921
Bernatowska E, Mikoluc B, Krzeski A, Piatosa B, Gromek I. Chronic rhinosinusitis in primary antibody immunodeficient patients. Int J Pediatr Otorhinolaryngol. 2006;70(9):1587‐1592.
Bjelac JA, Yonkof JR, Fernandez J. Differing performance of the warning signs for immunodeficiency in the diagnosis of pediatric versus adult patients in a two‐center tertiary referral population. J Clin Immunol. 2019;39(1):90‐98. doi:10.1007/s10875‐018–0582‐z
Bondioni MP, Duse M, Plebani A, et al. Pulmonary and sinusal changes in 45 patients with primary immunodeficiencies: computed tomography evaluation. J Comput Assist Tomogr. 2007;31(4):620‐628.
Chun JK, Lee TJ, Song JW, Linton JA, Kim DS. Analysis of clinical presentations of Bruton disease: a review of 20 years of accumulated data from pediatric patients at Severance Hospital. Yonsei Med J. 2008;49(1):28‐36. doi:10.3349/ymj.2008.49.1.28
Costa Carvalho BT, Nagao AT, Arslanian C, et al. Immunological evaluation of allergic respiratory children with recurrent sinusitis. Pediatr Allergy Immunol. 2005;16(6):534‐538.
Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3‐kinase δ syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597‐606.e4. doi:10.1016/j.jaci.2016.06.021
Criddle MW, Stinson A, Savliwala M, Coticchia J. Pediatric chronic rhinosinusitis: a retrospective review. Am J Otolaryngol. 2008;29(6):372‐378. doi:10.1016/j.amjoto.2007.11.003
Epstein MM, Gruskay F. Selective deficiency in pneumococcal antibody response in children with recurrent infections. Ann Allergy Asthma Immunol. 1995;75(2):125‐131.
Grzesk E, Dabrowska A, Urbanczyk A, Ewertowska M, Wysocki M, Koltan S. Common variable immunodeficiency: different faces of the same disease. Postepy Dermatol Alergol. 2021;38(5):873‐880. doi:10.5114/ada.2021.110067
Karadeniz EB, Aliyeva C, Aydemir S, et al. Chronic rhinosinusitis in patients with primary immunodeficiency. Int Arch Allergy Immunol. 2023;184(3):302‐310. doi:10.1159/000527265
Kutukculer N, Karaca NE, Demircioglu O, Aksu G. Increases in serum immunoglobulins to age‐related normal levels in children with IgA and/or IgG subclass deficiency. Pediatr Allergy Immunol. 2007;18(2):167‐173.
Lougaris V, Soresina A, Baronio M, et al. Long‐term follow‐up of 168 patients with X‐linked agammaglobulinemia reveals increased morbidity and mortality. J Allergy Clin Immunol. 2020;146(2):429‐437. doi:10.1016/j.jaci.2020.03.001
Lusk RP, Polmar SH, Muntz HR. Endoscopic ethmoidectomy and maxillary antrostomy in immunodeficient patients. Arch Otolaryngol Head Neck Surg. 1991;117(1):60‐63.
Mahdaviani SA, Darougar S, Mansouri D, et al. Pulmonary complications of predominantly antibody immunodeficiencies in a tertiary lung center. Interv Med Appl Sci. 2019;11(1):1‐7. doi:10.1556/1646.10.2018.49
Makary CA, Purnell PR, O'Brien D, Chaiban R, Demirdag YY, Ramadan H. Antibody deficiencies are more common in adult versus pediatric recurrent acute rhinosinusitis. Am J Otolaryngol. 2021;42(5):103004. doi:10.1016/j.amjoto.2021.103004
May A, Zielen S, von Ilberg C, Weber A. Immunoglobulin deficiency and determination of pneumococcal antibody titers in patients with therapy‐refractory recurrent rhinosinusitis. Eur Arch Otorhinolaryngol. 1999;256(9):445‐449.
Moazzami B, Yazdani R, Azizi G, et al. Respiratory complications in patients with hyper IgM syndrome. J Clin Immunol. 2019;39(6):557‐568. doi:10.1007/s10875‐019‐00650‐3
Moin M, Aghamohammadi A, Farhoudi A, et al. X‐linked agammaglobulinemia: a survey of 33 Iranian patients. Immunol Invest. 2004;33(1):81‐93.
Moin M, Aghamohammadi A, Kouhi A, et al. Ataxia‐telangiectasia in Iran: clinical and laboratory features of 104 patients. Pediatr Neurol. 2007;37(1):21‐28.
Ogershok PR, Hogan MB, Welch JE, Corder WT, Wilson NW. Spectrum of illness in pediatric common variable immunodeficiency. Ann Allergy Asthma Immunol. 2006;97(5):653‐656.
Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46(10):1547‐1554. doi:10.1086/587669
Perkins T, Rosenberg JM, Le Coz C, et al. Smith‐Magenis syndrome patients often display antibody deficiency but not other immune pathologies. J Allergy Clin Immunol Pract. 2017;5(5):1344‐1350.e3. doi:10.1016/j.jaip.2017.01.028
Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X‐linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221‐230. doi:10.1006/clim.2002.5241
Quezada A, Norambuena X, Inostroza J, Rodriguez J. Specific antibody deficiency with normal immunoglobulin concentration in children with recurrent respiratory infections. Allergol Immunopathol (Madr). 2015;43(3):292‐297. doi:10.1016/j.aller.2014.07.009
Quinti I, Soresina A, Spadaro G, et al. Long‐term follow‐up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27(3):308‐316. doi:10.1007/s10875‐007–9075‐1
Ramesh S, Brodsky L, Afshani E, et al. Open trial of intravenous immune serum globulin for chronic sinusitis in children. Ann Allergy Asthma Immunol. 1997;79(2):119‐124. doi:10.1016/s1081‐1206(10)63097‐9
Ramirez‐Vargas N, Arablin‐Oropeza SE, Mojica‐Martinez D, et al. Clinical and immunological features of common variable immunodeficiency in Mexican patients. Allergol Immunopathol (Madr). 2014;42(3):235‐240. doi:10.1016/j.aller.2013.01.007
Roifman CM, Lederman HM, Lavi S, Stein LD, Levison H, Gelfand EW. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med. 1985;79(2):171‐174.
Roifman CM, Gelfand EW. Replacement therapy with high dose intravenous gamma‐globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr Infect Dis J. 1988;7(5):S92‐6.
Rusconi F, Panisi C, Dellepiane RM, et al. Pulmonary and sinus diseases in primary humoral immunodeficiencies with chronic productive cough. Arch Dis Child. 2003;88(12):1101‐1105.
Scadding GK, Lund VJ, Darby YC, Navas‐Romero J, Seymour N, Turner MW. IgG subclass levels in chronic rhinosinusitis. Rhinology. 1994;32(1):15‐19.
Sethi DS, Winkelstein JA, Lederman H, Loury MC. Immunologic defects in patients with chronic recurrent sinusitis: diagnosis and management. Otolaryngol Head Neck Surg. 1995;112(2):242‐247.
Shackelford PG, Polmar SH, Mayus JL, Johnson WL, Corry JM, Nahm MH. Spectrum of IgG2 subclass deficiency in children with recurrent infections: prospective study. J Pediatr. 1986;108(5):647‐653.
Shapiro GG, Virant FS, Furukawa CT, Pierson WE, Bierman CW. Immunologic defects in patients with refractory sinusitis. Pediatrics. 1991;87(3):311‐316.
Silk HJ, Ambrosino D, Geha RS. Effect of intravenous gammaglobulin therapy in IgG2 deficient and IgG2 sufficient children with recurrent infections and poor response to immunization with Hemophilus influenzae type b capsular polysaccharide antigen. Ann Allergy. 1990;64(1):21‐25.
Singh YN, Khare SD, Malaviya AN. Common variable immunodeficiency (CVID) in northern India. Asian Pac J Allergy Immunol. 1994;12(2):169‐172.
Snow DG, Hansel TT, Williams PE, Drake‐Lee AB, Thompson RA. Sinus computerized tomography in primary hypogammaglobulinaemia. 1993:1008‐1010.
Song CH, Estevez D, Chernikova D, Hernandez F, Sakai‐Bizmark R, Stiehm R. Low baseline pneumococcal antibody titers predict specific antibody deficiency, increased upper respiratory infections, and allergy sensitization. Allergy Rhinol (Providence). 2020;11(101570968):2152656719900338. doi:10.1177/2152656719900338
Trakultivakorn M, Ochs HD. X‐linked agammaglobulinemia in northern Thailand. Asian Pac J Allergy Immunol. 2006;24(1):57‐63.
Umetsu DT, Ambrosino DM, Quinti I, Siber GR, Geha RS. Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG‐subclass deficiency. N Engl J Med. 1985;313(20):1247‐1251.
Urschel S, Kayikci L, Wintergerst U, Notheis G, Jansson A, Belohradsky BH. Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J Pediatr. 2009;154(6):888‐894. doi:10.1016/j.jpeds.2008.12.020
Vanlerberghe L, Joniau S, Jorissen M. The prevalence of humoral immunodeficiency in refractory rhinosinusitis: a retrospective analysis. B‐ENT. 2006;2(4):161‐166.
Vu QV, Wada T, Le HTM, et al. Clinical and mutational features of Vietnamese children with X‐linked agammaglobulinemia. BMC pediatrics. 2014;14(100967804):129. doi:10.1186/1471‐2431‐14‐129
Williams P, White A, Wilson JA, Yap PL. Penetration of administered IgG into the maxillary sinus and long‐term clinical effects of intravenous immunoglobulin replacement therapy on sinusitis in primary hypogammaglobulinaemia. Acta Otolaryngol. 1991;111(3):550‐555. doi:10.3109/00016489109138382
Winkelstein JA, Marino MC, Ochs H, et al. The X‐linked hyper‐IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 2003;82(6):373‐384.
Winkelstein JA, Marino MC, Lederman HM, et al. X‐linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85(4):193‐202. doi:10.1097/01.md.0000229482.27398.ad
Mandava S, Lin J, Joshua C, Payne SC, Mattos JL. Evaluation and workup of immunodeficiencies in recurrent acute rhinosinusitis: a scoping review. Int Forum Allergy Rhinol. 2023;13(6):1017‐1023. doi:10.1002/alr.23106
Jamee M, Moniri S, Zaki‐Dizaji M, et al. Clinical, immunological, and genetic features in patients with activated PI3Kdelta syndrome (APDS): a systematic review. Clin Rev Allergy Immunol. 2020;59(3):323‐333. doi:10.1007/s12016‐019‐08738‐9
Samargandy S, Grose E, Chan Y, Monteiro E, Lee JM, Yip J. Medical and surgical treatment outcomes in patients with chronic rhinosinusitis and immunodeficiency: a systematic review. Int Forum Allergy Rhinol. 2021;11(2):162‐173. doi:10.1002/alr.22647
Bonilla FA, Barlan I, Chapel H, et al. International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4(1):38‐59. doi:10.1016/j.jaip.2015.07.025
Picard C, Bobby Gaspar H, Al‐Herz W, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96‐128. doi:10.1007/s10875‐017‐0464‐9
Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;130(3):S1‐S24. doi:10.1016/j.jaci.2012.07.002
Makary CA, Luong AU, Azar A, et al. Evaluation and treatment of rhinosinusitis with primary antibody deficiency in adults: evidence‐based review with recommendations. Int Forum Allergy Rhinol. 2023;13(12):2205‐2230. doi:10.1002/alr.23206
Agarwal S, Cunningham‐Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007;99(3):281‐283. doi:10.1016/s1081‐1206(10)60665‐5
Bareiss AK, Kattar N, Tivis R, et al. Health‐care utilization for sinusitis after pneumococcal vaccination in patients with low antibody titers. Int Forum Allergy Rhinol. 2022;12(8):1018‐1024. doi:10.1002/alr.22954
de Sévaux JL, Venekamp RP, Lutje V, et al. Pneumococcal conjugate vaccines for preventing acute otitis media in children. Cochrane Database Syst Rev. 2020;11(11):Cd001480. doi:10.1002/14651858.CD001480.pub6
Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135(2):255‐263. doi:10.1016/j.clim.2009.10.003
Hernandez‐Trujillo HS, Chapel H. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012;169(1):57‐69. doi:10.1111/j.1365‐2249.2012.04588.x
Onakpoya IJ, Hayward G, Heneghan CJ. Antibiotics for preventing lower respiratory tract infections in high‐risk children aged 12 years and under. Cochrane Database Syst Rev. 2015;2015(9):Cd011530. doi:10.1002/14651858.CD011530.pub2
Grammatikos A, Albur M, Gompels M, Barnaby CL, Allan S, Johnston S. Antibiotic prophylaxis for the prevention of respiratory tract infections in antibody deficient patients: a retrospective cohort study. Clinical Infection in Practice. 2020;7–8:100048. doi:10.1016/j.clinpr.2020.100048
Smits BM, Kleine Budde I, de Vries E, et al. Immunoglobulin replacement therapy versus antibiotic prophylaxis as treatment for incomplete primary antibody deficiency. J Clin Immunol. 2021;41(2):382‐392. doi:10.1007/s10875‐020‐00841‐3
Lucas M, Lee M, Lortan J, Lopez‐Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354‐1360. doi:10.1016/j.jaci.2010.02.040
Szczawinska‐Poplonyk A, Schwartzmann E, Bukowska‐Olech E, et al. The pediatric common variable immunodeficiency—from genetics to therapy: a review. Eur J Pediatr. 2022;181(4):1371‐1383. doi:10.1007/s00431‐021‐04287‐6